US 10272099
Tumor-selective combination therapy
granted A61KA61K31/131A61K31/353
Quick answer
US patent 10272099 (Tumor-selective combination therapy) held by The Board of Regents of the University of Texas System expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K31/131, A61K31/353, A61K31/4738, A61K31/4745